IgA肾病生物预后预测标志物研究进展
Advances in Biological Prognostic Predictive Markers for IgA Nephropathy
DOI: 10.12677/ACM.2023.13112483, PDF, HTML, XML, 下载: 251  浏览: 340 
作者: 迪丽努尔·图尔荪托合提, 欧云塔娜, 张 蕾*:新疆医科大学第五附属医院肾内科,新疆 乌鲁木齐
关键词: IgA肾病生物标志物预后IgA Nephropathy Biomarkers Prognosis
摘要: IgA肾病是世界范围内发病率最高的原发性肾小球疾病,其临床表现和预后的个体差异极大,因此早期发现影响预后的因素尤为重要。随着对IgAN发病机制的进一步研究,一些新的、更简便的的生物标志物被发现,包括甘油三酯与高密度脂蛋白胆固醇比值(TG/HDL-C)、微小RNA、IgM的沉积、白细胞介素-6、中性粒细胞–淋巴细胞比值(NLR)、血小板与白蛋白比值(PAR)、血小板与淋巴细胞比值(PLR)等,为早期识别、干预高危患者提供了更多的可能性,都可作为IgA肾病预后预测标志物。
Abstract: IgA nephropathy is the primary glomerular disease with the highest incidence worldwide, and its clinical manifestations and prognosis are characterized by great individual variability, making early detection of factors affecting prognosis particularly important. With further studies on the patho-genesis of IgAN, some new and easier biomarkers have been discovered, including triglyceride to high-density lipoprotein cholesterol ratio (TG/HDL-C), microRNA, IgM deposition, interleukin-6, neutrophil-lymphocyte ratio (NLR), platelet to albumin ratio (PAR), and platelet-to-lym- phocyte ra-tio (PLR), etc., which provide more possibilities for early identification and intervention in high-risk patients, can all be used as prognostic predictive markers for IgA nephropathy.
文章引用:迪丽努尔·图尔荪托合提, 欧云塔娜, 张蕾. IgA肾病生物预后预测标志物研究进展[J]. 临床医学进展, 2023, 13(11): 17707-17712. https://doi.org/10.12677/ACM.2023.13112483

1. 引言

IgA肾病(IgAN)是最常见的原发性肾小球肾炎,也是终末期疾病(ESRD)的主要原因,其中20%~40%的IgAN患者在最初诊断10~20年后达到ESRD [1] 。

IgAN需通过肾组织活检进行确诊和判断预后,但在临床实践中,肾活检具有持续血尿、肾脏包膜下血肿、穿刺部位感染等相关风险。因此,寻找可靠的基于血清、血浆、尿液等的预后标志物变得尤为重要。近年研究发现,通过检测生物标志物水平可诊断或评估病情进展,进一步指导临床治疗,本文就此做一综述。

2. 甘油三酯与高密度脂蛋白胆固醇比值(TG/HDL-C)

甘油三酯与高密度脂蛋白胆固醇(TG/HDL-C)比值是一种易于使用的动脉粥样硬化和预后标志物,近年来受到越来越多的关注。然而,TG/HDL-C是否与IgA肾病(IgAN)患者的预后相关仍不清楚。近Pei等 [2] 就大样本1146例来自四川大学华西医院肾活检的患者进行研究。发现TG/HDL-C与eGFR呈负相关,但与蛋白尿呈正相关,TG/HDL-C比值较高的患者易患高血压和更严重的病理病变伴小管萎缩/间质纤维化。高TG/HDL比值与IgAN患者肾生存较差密切相关,TG/HDL-C比值较高是ESRD的独立预测指标。H.H. Nguyen等 [3] 对152例慢性肾病患者进行描述性横断面研究。研究发现TG/HDL-C与eGFR呈中等负相关,TG/HDL-C与ACR呈弱正相关,得出结论TG/HDL-C比值是CKD相关的危险因素,在监测和评估CKD进展风险方面具有重要意义。

3. 相关免疫复合物的沉积

3.1. 半乳糖缺乏型系列标志物

在IgA肾病中已提出多重打击假说来解释其病理生理学,血液循环中血清Gd-IgA1 (半乳糖缺乏型IgA1)水平的升高,然后刺激机体产生自身抗体(GdIgA1-IgG、GdIgA1-IgA),相互结合形成循环免疫复合物沉积在肾小球系膜区造成肾脏损伤 [4] 。日本一项研究发现 [5] IgA肾病中Gd-IgA1沉积程度与eGFR呈负相关,s-Gd-IgA1升高和m-Gd-IgA1沉积是反映IgAN严重程度的可靠诊断因素,其中伴有肾小球硬化和小管间质病变的IgAN患者s-Gd-IgA1水平显著升高。总而言之,Gd-IgA1可能是IgAN患者的重要生物标志物。Placzek等发现 [6] ,肾小球内IgG与Gd-IgA1以多聚糖依赖方式形成Gd-IgA1的自身抗原抗体Gd-IgA1 IgG。Gd-IgA1 IgG在抗体分子的互补决定区特有的排列顺序,使之易与半乳糖缺乏的聚糖结合。86.7%的IgAN患者血清Gd-IgA1 IgG > 1.536,仅有1.4%健康对照人群的血清Gd-IgA1 IgG > 1.536。因此上述过程中的GdIgA1分子、GdIgA1-IgG、Gd IgA1-IgA等复合物均被认为有望成为未来IgAN的无创诊断标志物。

3.2. IgM的沉积

LiTa等人 [7] 在一项样本为1239名患者的多中心观察性研究中发现,系膜IgM沉积与组织学活性、临床严重程度和肾脏预后相关,系膜IgM沉积的程度预测预后是独立于MEST-C评分的,是IgAN患者肾脏预后不良的独立危险因素。在一项纳入116名IgAN儿童的研究中发现 [8] ,合并系膜IgM和C3沉积的患儿对比未合并IgM和C3沉积的患儿,肾功能不全发生率会更高,肾脏病理严重程度越高,得出肾小球系膜IgM沉积是原发性IgAN患儿肾脏预后不良的独立危险因素。

3.3. C4d的沉积

在一项系统回顾和荟萃分析中 [9] ,共纳入12项研究,1251例患者。肾小球C4d沉积的患病率为34%,C4d沉积患者估计肾小球滤过率较低以及较高的尿蛋白–肌酐比值、24小时尿蛋白排泄增多、更高的高血压风险。肾小球C4d沉积与高牛津评分相关,包括M1、E1、S1和T1/2病变(均P ≤ 0.006)。C4d沉积患者使用肾素–血管紧张素系统阻滞剂和免疫抑制剂的比例较高。肾小球C4d沉积与不良预后相关,可能是IgAN疾病预测的有用生物标志物。几项针对成人的大型研究表明,肾小球C4d沉积在IgAN中具有预后价值。然而,关于C4d沉积在IgAN或HSPN (紫癜肾病)患儿中的临床价值的相关研究很少。Wu等人 [10] 对患有IgAN或HSPN的儿童患者进行了回顾性队列研究,发现IgAN和HSPN患者肾小球C4d沉积与系膜细胞增多和肾小球IgM沉积有关。肾小球C4d沉积可能是IgAN患儿eGFR下降的危险因素。

4. 微小RNA

4.1. 血清miRNA

IgA肾病的预后多种多样且存在个体差异,高血压、大量蛋白尿、病理分型是影响IgA肾病预后的因素。IgA肾病病理特征中,肾间质的纤维化是影响预后的独立因素 [11] 。miR-29家族在IgAN的发展过程中起着重要作用,先前在大鼠或小鼠中进行的研究表明,下调miR-29家族成员可加重肾间质纤维化 [12] [13] 。Hennino等人 [14] 探讨了miR-21-5p、miR-199a-5p和miR-214-3p与IgAN病理变化的关系,在肾间质纤维化的患者中,miR-21-5p、miR-199a-5p和miR-214-3p的表达水平显著增加。Fan等人 [15] 的研究表明,IgA肾病中血清miR-192表达水平较低与肾间质纤维化和肾小管萎缩程度较高有关,因此在IgA肾病的发展过程中,检测血清miR-192表达水平能间接反映IgA肾病肾纤维化程度,可能具有成为IgA肾病预后的潜力。

4.2. 尿液miRNA

胞外体miRNA是新近发现的一种细胞外miRNA [16] 。Min等 [17] 发现IgAN患者与健康对照组尿外泌体miRNA谱存在显著差异。这些外泌体mirna,如miR-29c,miR-146a和miR-205可以作为IgAN的新型非侵入性生物标志物。Ye等 [18] 发现与对照组相比,IgAN患者的外泌体排泄明显增加,并与蛋白尿水平和肾小管损伤相关。更重要的是,尿外泌体排泄与更大的组织学活动(系膜细胞增多、新月状和毛细血管内细胞增多)相关。炎症相关mRNA的分析显示,IgAN患者的外泌体趋化因子(C-C基序)配体2 (CCL2)上调。在一项验证性研究中,与健康对照、微小变化疾病和膜性肾病患者相比,CCL2在IgAN患者中完全高表达。此外,在IgAN中发现外泌体CCL2与肾小球滤过率水平之间存在相关性。外泌体CCL2与小管间质炎症和C3沉积相关。肾活检时的高CCL2水平与随后的肾功能恶化有关。因此,尿外泌体和外泌体CCL2 mRNA是反映IgAN活动性肾组织损伤和肾功能恶化的有希望的生物标志物。在一项从29例IgAN患者和29例健康对照中分离尿外泌体的研究中发现 [19] ,与健康对照相比,hsa-miR-451a和hsa-let-7d-3p在IgAN患者中上调。Hsa-miR-451a与Lee’s分级、24小时尿蛋白排泄量相关。Hsa-let-7d-3p与Lee’s分级、UPE、血清肌酐和肾小球滤过率相关。这些发现表明,hsa-miR-451a和hsa-let-7d-3p可以作为评估IgAN的无创生物标志物。

5. 细胞炎症因子

5.1. 白细胞介素-6 (Interleukin-6, IL-6)

IgAN的发生、发展中常存在粘膜感染和炎症因子的参与,而IL-6是一种参与集体炎症反应和B细胞成熟过程的细胞因子。有学者发现,IL-6通过增强信号转导几转录激活因子磷酸化导致Gd-IgA1过度产生,且这种IL-6介导的Gd-IgA1的大量形成可被酪氨酸激酶/信号转导及转录激活因子信号通路的抑制剂阻断 [20] 。因此,IL-6与Gd-IgA1的形成密切相关。

5.2. 中性粒细胞–淋巴细胞比值

中性粒细胞–淋巴细胞比值(neutrophil-lymphocyte ratio, NLR)是近年来研究较多的反映机体免疫和慢性炎症状态的标志物,因其易于检测而备受关注 [21] [22] 。已在恶性肿瘤、慢性肾病、糖尿病肾病、肾癌、血液透析患者中得到广泛研究,被证实与病情进展及预后密切相关,同时被认为是鉴别诊断及预测疾病预后的有用指标 [23] [24] [25] [26] [27] 。在Wang等人 [28] 对966名IgAN患者的一项回顾性研究中发现,与WBCs、PLTs、LYs、PLR和NE等正常炎症因子相比,NLR是最好的预测指标,发现NLR与血清肌酐和24小时尿蛋白呈正相关,与eGFR呈负相关。NLR高的IgAN患者也更容易患上高血压。此外,具有高NLR的IgAN患者往往有更严重的肾脏病理病变,结果分析得到中性粒细胞与淋巴细胞比率是IgA肾病患者疾病进展的重要且独立的危险因素,特别是中性粒细胞与淋巴细胞比率越高的IgA肾病患者,更应该重视前期的干预与治疗。在Li等人研究中 [29] ,共纳入1151例定期随访的IgAN患者和251名健康志愿者。研究发现,与对照组相比,IgAN患者的WBC、NE、NLR和PLR水平升高,LY水平降低。在单因素生存分析中,WBC、NE和NLR与IgAN的进展有显著相关性,而NLR具有更高的相关性。

5.3. 血小板相关参数

血小板相关参数,包括血小板(PLT),血小板与白蛋白比值(PAR)和血小板与淋巴细胞比值(PLR),在除了止血,血小板也可以触发和通过与免疫细胞相互作用而加重炎症分泌促炎细胞因子 [30] ,多项研究一致报告PAR和PLR与炎症有关,并被描述为新发炎症指标 [31] [32] [33] 。在一项观察性研究中 [34] ,纳入330名IgAN患者分成三组(PLR < 106、106 ≤ PLR ≤ 137和PLR > 137),研究发现,PLR > 137组比其他两组更容易出现肾功能不良,PLR > 137是IgAN患者肾存活率低的独立预后因素。亚组分析显示,PLR对女性患者或eGFR低于60 mL/min/1.73m2的患者仍然具有预后价值。得出结论,基线PLR是IgAN患者,尤其是女性患者肾存活率低的独立预后因素。在一项纳入966例IgAN患者的回顾性研究中 [35] ,发现PLR和PAR与IgAN的肾脏预后密切相关。根据病理结果和实验室结果,相比与PLR,PAR似乎是一个更好的肾脏不良预后指标,高PAR患者似乎有更严重的临床表现和病理病变。这意味着PAR是最重要的仅有血小板相关参数的独立危险因素。

6. 小结与展望

目前IgAN的无创诊断尚未在临床上大范围展开,但近年来的部分研究已经证实了其科学性和可行性。多种标志物联合评估可能会提高准确率,对生物标志物的动态监测也有利于判断疗效及预后,但需要更多研究的证实。相信随着未来研究的深入,我们可以实现通过无创标志物判断病情严重程度、预测疾病恶化进展以及早期干预。

NOTES

*通讯作者。

参考文献

[1] Rodrigues, J.C., Haas, M. and Reich, H.N. (2017) IgA Nephropathy. Clinical Journal of the American Society of Neph-rology, 12, 677-686.
https://doi.org/10.2215/CJN.07420716
[2] Pei, G., Qin, A., Dong, L., Wang, S., Liu, X., Yang, D., Tan, J., Zhou, X., Tang, Y. and Qin, W. (2022) Prognostic Value of Triglyceride to High-Density Lipoprotein Cholesterol Ratio (TG/HDL-C) in IgA Nephropathy Patients. Frontiers in Endocrinology (Lausanne), 13, Article ID: 877794.
https://doi.org/10.3389/fendo.2022.877794
[3] Nguyen, H.H., Tran, H.H., Nguyen, L.T., Nguyen, T., Nguyen, N.A., Vi, M.T. and Nguyen, K.T. (2022) TG/HDL-C Ratio Is a Risk Factor Associated with CKD: Use in As-sessing the Risk of Progression of CKD. Pathophysiology, 29, 374-382.
https://doi.org/10.3390/pathophysiology29030029
[4] Kant, S., Kronbichler, A., Sharma, P. and Geetha, D. (2022) Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: A Review. American Journal of Kidney Diseases, 79, 582-600.
https://doi.org/10.1053/j.ajkd.2021.07.019
[5] Wada, Y., Matsumoto, K., Suzuki, T., Saito, T., Kanazawa, N., Tachibana, S., Iseri, K., Sugiyama, M., Iyoda, M. and Shibata, T. (2018) Clinical Significance of Serum and Mesangial Galactose-Deficient IgA1 in Patients with IgA Nephropathy. PLOS ONE, 13, e0206865.
https://doi.org/10.1371/journal.pone.0206865
[6] Placzek, W.J., Yanagawa, H., Makita, Y., Renfrow, M.B., Jul-ian, B.A., Rizk, D.V., Suzuki, Y., Novak, J. and Suzuki, H. (2018) Serum Galactose-Deficient-IgA1 and IgG Autoanti-bodies Correlate in Patients with IgA Nephropathy. PLOS ONE, 13, e0190967.
https://doi.org/10.1371/journal.pone.0190967
[7] Tan, L., Tang, Y., Pei, G.Q., Zhong, Z.X., Tan, J.X., Ma, Y., Wang, D.G., Zhou, L., Sheikh-Hamad, D. and Qin, W. (2021) Mesangial IgM Deposition Predicts Renal Outcome in Patients with IgA Nephropathy: A Multicenter, Observational Study. Clinical and Experimental Medicine, 21, 599-610.
https://doi.org/10.1007/s10238-021-00703-1
[8] Xiong, L., Liu, L., Tao, Y. and Guo, H. (2023) Clinical Signifi-cance of IgM and C3 Deposition in Children with Primary Immunoglobulin A Nephropathy. Journal of Nephrology.
https://doi.org/10.1007/s40620-023-01724-7
[9] Jiang, Y., Zan, J., Shi, S., Hou, W., Zhao, W., Zhong, X., Zhou, X., Lv, J. and Zhang, H. (2021) Glomerular C4d Deposition and Kidney Disease Progression in IgA Nephropathy: A Systematic Review and Meta-Analysis. Kidney Medicine, 3, 1014-1021.
https://doi.org/10.1016/j.xkme.2021.06.009
[10] Wu, D., Lei, L., Zhang, H., Yao, X., Chen, Z., Zhang, N., Ni, J., Ling, C., Liu, X. and Chen, X. (2023) Clinical Relevance of Glomerular C4d Deposition in Children with Early IgA Nephropathy or Henoch-Schönlein Purpura Nephropathy. Pediatric Nephrology, 38, 431-438.
https://doi.org/10.1007/s00467-022-05585-3
[11] Ramanathan, K. and Padmanabhan, G. (2020) MiRNAs as Po-tential Biomarker of Kidney Diseases: A Review. Cell Biochemistry & Function, 38, 990-1005.
https://doi.org/10.1002/cbf.3555
[12] Qin, W., Chung, A., Huang, X., Meng, X., Hui, D., Yu, C., Sung, J. and Lan, H. (2011) TGF-β/Smad3 Signaling Promotes Renal Fibrosis by Inhibiting miR-29. Journal of the American Society of Nephrology: JASN, 22, 1462-1474.
https://doi.org/10.1681/ASN.2010121308
[13] Fang, Y., Yu, X., Liu, Y., Kriegel, A., Heng, Y., Xu, X., Liang, M. and Ding, X. (2013) miR-29c Is Downregulated in Renal Interstitial Fibrosis in Humans and Rats and Restored by HIF-α Activation. American Journal of Physiology. Renal Physiology, 304, F1274-F1282.
https://doi.org/10.1152/ajprenal.00287.2012
[14] Hennino, M., Buob, D., Van der Hauwaert, C., Gnemmi, V., Jomaa, Z., Pottier, N., Savary, G., Drumez, E., Noël, C., Cauffiez, C. and Glowacki, F. (2016) miR-21-5p Renal Expres-sion Is Associated with Fibrosis and Renal Survival in Patients with IgA Nephropathy. Scientific Reports, 6, Article No. 27209.
https://doi.org/10.1038/srep27209
[15] Fan, Q., Lu, R., Zhu, M., Yan, Y., Guo, X., Qian, Y., Zhang, L., Dai, H., Ni, Z. and Gu, L. (2019) Serum miR-192 Is Related to Tubulointerstitial Lesion and Short-Term Disease Pro-gression in IgA Nephropathy. Nephron, 142, 195-207.
https://doi.org/10.1159/000497488
[16] Mizutani, K., Kawakami, K., Horie, K., Fujita, Y., Kameyama, K., Kato, T., Nakane, K., Tsuchiya, T., Yasuda, M., Masunaga, K., et al. (2019) Urinary Exosome as a Potential Biomarker for Uri-nary Tract Infection. Cellular Microbiology, 21, e13020.
https://doi.org/10.1111/cmi.13020
[17] Min, Q.H., Chen, X.M., Zou, Y.Q., Zhang, J., Li, J., Wang, Y., Li, S.Q., Gao, Q.F., Sun, F., Liu, J., et al. (2018) Differential Expression of Urinary Exosomal MicroRNAs in IgA Nephropathy. Journal of Clinical Laboratory Analysis, 32, e22226.
https://doi.org/10.1002/jcla.22226
[18] Feng, Y., Lv, L.L., Wu, W.J., Li, Z.L., Chen, J., Ni, H.F., Zhou, L.T., Tang, T.T., Wang, F.M., Wang, B., et al. (2018) Urinary Exosomes and Exosomal CCL2 mRNA as Biomarkers of Active Histologic Injury in IgA Nephropathy. The American Journal of Pathology, 188, 2542-2552.
https://doi.org/10.1016/j.ajpath.2018.07.017
[19] Li, S., Hao, H., Li, R. and Guo, S. (2022) Urinary Exosomal Mi-croRNAs as New Noninvasive Biomarkers of IgA Nephropathy. The Tohoku Journal of Experimental Medicine, 256, 215-223.
https://doi.org/10.1620/tjem.256.215
[20] Yamada, K., Huang, Z.Q., Raska, M., Reily, C., Anderson, J.C., Suzuki, H., Ueda, H., Moldoveanu, Z., Kiryluk, K., Suzuki, Y., et al. (2017) Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy. Kidney International Reports, 2, 1194-1207.
https://doi.org/10.1016/j.ekir.2017.07.002
[21] Park, C.H., Han, D.S., Jeong, J.Y., Eun, C.S., Yoo, K.S., Jeon, Y.C. and Sohn, J.H. (2016) The Optimal Cut-Off Value of Neutrophil-to-Lymphocyte Ratio for Predicting Prognosis in Adult Patients with Henoch-Schönlein Purpura. PLOS ONE, 11, e0153238.
https://doi.org/10.1371/journal.pone.0153238
[22] Nagy, G.R., Kemény, L. and Bata-Csörgő, Z. (2017) Neutro-phil-to-Lymphocyte Ratio: A Biomarker for Predicting Systemic Involvement in Adult IgA Vasculitis Patients. Journal of the European Academy of Dermatology and Venereology, 31, 1033-1037.
https://doi.org/10.1111/jdv.14176
[23] Zhao, W.M., Tao, S.M. and Liu, G.L. (2020) Neutrophil-to-Lymphocyte Ratio in Relation to the Risk of All-Cause Mortality and Cardiovascular Events in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Renal Failure, 42, 1059-1066.
https://doi.org/10.1080/0886022X.2020.1832521
[24] Zhang, J., Zhang, R., Wang, Y., Wu, Y., Li, H., Han, Q., Guo, R., Wang, T., Wang, J., Grung, P. and Liu, F. (2019) Effects of Neutrophil-Lymphocyte Ratio on Renal Function and Histologic Lesions in Patients with Diabetic Nephropathy. Nephrology (Carlton), 24, 1115-1121.
https://doi.org/10.1111/nep.13517
[25] Shao, Y., Wu, B., Jia, W., Zhang, Z., Chen, Q. and Wang, D. (2020) Prognostic Value of Pretreatment Neutrophil-to- Lymphocyte Ratio in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. BMC Urology, 20, Article No. 90.
https://doi.org/10.1186/s12894-020-00665-8
[26] Ao, G., Wang, Y., Qi, X., Wang, F. and Wen, H. (2021) Association of Neutrophil-to-Lymphocyte Ratio and Risk of Cardio-vascular or All-Cause Mortality in Chronic Kidney Disease: A Meta-Analysis. Clinical and Experimental Nephrology, 25, 157-165.
https://doi.org/10.1007/s10157-020-01975-9
[27] Simonaggio, A., Elaidi, R., Fournier, L., Fabre, E., Ferrari, V., Borchiellini, D., Thouvenin, J., Barthelemy, P., Thibault, C., Tartour, E., et al. (2020) Variation in Neutrophil to Lymphocyte Ratio (NLR) as Predictor of Outcomes in Metastatic Renal Cell Carcinoma (mRCC) and Non-Small Cell Lung Cancer (mNSCLC) Patients Treated with Nivolumab. Cancer Immunology, Immunotherapy, 69, 2513-2522.
https://doi.org/10.1007/s00262-020-02637-1
[28] Wang, S., Dong, L., Pei, G., Jiang, Z., Qin, A., Tan, J., Tang, Y. and Qin, W. (2021) High Neutrophil-to-Lymphocyte Ratio Is an Independent Risk Factor for End Stage Renal Diseases in IgA Nephropathy. Frontiers in Immunology, 12, Article ID: 700224.
https://doi.org/10.3389/fimmu.2021.700224
[29] Li, Q., Chen, P., Shi, S., Liu, L., Lv, J., Zhu, L. and Zhang, H. (2020) Neutrophil-to-Lymphocyte Ratio as an Independent Inflammatory Indicator of Poor Prognosis in IgA Nephropa-thy. International Immunopharmacology, 87, Article ID: 106811.
https://doi.org/10.1016/j.intimp.2020.106811
[30] Holinstat, M. (2017) Normal Platelet Function. Cancer and Me-tastasis Reviews, 36, 195-198.
https://doi.org/10.1007/s10555-017-9677-x
[31] Kumarasamy, C., Tiwary, V., Sunil, K., Suresh, D., Shetty, S., Muthukaliannan, G.K., Baxi, S. and Jayaraj, R. (2021) Prognostic Utility of Platelet-Lymphocyte Ratio, Neutro-phil-Lymphocyte Ratio and Monocyte-Lymphocyte Ratio in Head and Neck Cancers: A Detailed PRISMA Compliant Systematic Review and Meta-Analysis. Cancers (Basel), 13, Article No. 4166.
https://doi.org/10.3390/cancers13164166
[32] Li, L., Yu, J. and Zhou, Z. (2021) Platelet-Associated Parameters in Patients with Psoriasis: A PRISMA-Compliant Systematic Review and Meta-Analysis. Medicine (Baltimore), 100, e28234.
https://doi.org/10.1097/MD.0000000000028234
[33] Li, L.Q., Bai, Z.H., Zhang, L.H., Zhang, Y., Lu, X.C., Zhang, Y., Liu, Y.K., Wen, J. and Li, J.Z. (2020) Meta-Analysis of Hematological Biomarkers as Reliable Indicators of Soft Tissue Sarcoma Prognosis. Frontiers in Oncology, 10, Article No. 30.
https://doi.org/10.3389/fonc.2020.00030
[34] Chang, D., Cheng, Y., Luo, R., Zhang, C., Zuo, M., Xu, Y., Dai, W., Li, Y., Han, M., He, X., et al. (2021) The Prognostic Value of Platelet-to-Lymphocyte Ratio on the Long-Term Renal Survival in Patients with IgA Nephropathy. International Urology and Nephrology, 53, 523-530.
https://doi.org/10.1007/s11255-020-02651-3
[35] Tan, J., Song, G., Wang, S., Dong, L., Liu, X., Jiang, Z., Qin, A., Tang, Y. and Qin, W. (2022) Platelet-to-Albumin Ratio: A Novel IgA Nephropathy Prognosis Predictor. Frontiers in Immunology, 13, Article ID: 842362.
https://doi.org/10.3389/fimmu.2022.842362